ClinicalTrials.gg
RecruitingNCT06515717ExoKetUpdated Jul 29, 2024

Exogenous Ketones and Behavior

An interventional study of ketone ester and dextrose (placebo) in Behavior, sponsored by German Institute of Human Nutrition. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by German Institute of Human Nutrition · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Behavior with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Behavior · Germany.

Planned enrollment
17th of 21
45 · median 175
Started
2024
with 2 others
No phase
19 of 25
4 open now
Registered
22nd of 25
by date
Lead sponsor
5 of 25
German Institute of Human Nutrition

Among the 25 studies in Behavior with a site in Germany, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 19 with no phase, and was the 22nd registered.

Behavior

1,574 studies on the registry are indexed under Behavior; 312 are open to participants now.

Browse Behavior studies →

Open to participants now

4 of the 25 studies in Behavior with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 176 Behavior studies recruiting now, 76 (43%) set no upper age limit and 72 (41%) stop at 75 or younger; 57 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Behavior with a site in Germany, or all of them as a file.
02

Study summary

The study will examine the effect of exogenous ketone ester on behavior and metabolism using Virtual Reality and computerizes behavioral tasks.

Read the detailed description

This study investigates the effects of exogenous ketone ester on behavior, cognition, and metabolism over one week of consumption. Using a within-subjects, randomized, crossover design, participants will undergo two phases: one with the ketone ester supplement and one with a calorie- and taste-matched placebo. The study includes four lab visits: visits 1 and 3 mark the first day of each intervention, while visits 2 and 4 mark the last day. During each visit, participants will complete behavioral tasks, questionnaires, and blood tests. Additionally, participants will record their food intake via an app and collect stool samples throughout the intervention.

03

Conditions studied

  • Behavior

Keywords

  • ketones
  • human cognition
  • metabolism
  • anxiety
  • intervention
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consent to participate
  • Fluent in German
  • Physically healthy. No regular medication
  • No drug use 1 week prior to the study
  • 18-31 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Former or current illnesses of:
  • Brain or mind (including eating disorders, personality disorders, alcohol, drugs or drug dependence, neurological disorders other than occasional headache; depression or anxiety disorder excluded)
  • Heart or blood circulation
  • Gastro-intestinal or endocrine disorders
  • Liver or kidney disorders
  • Electrolyte imbalance
  • Other serious past or present medical conditions (for example, metabolic syndrome, diabetes, cancer)
  • Pregnancy
  • Extreme athletes (>2h/day intense work-out; casual cycling or walking is ok)
  • Menopause (post menopause is ok)
  • Ketogenic diet, ketogenic supplement intake, intermittent fasting or calorie restricted diet during preceding 4 weeks of study participation
  • Fear of blood draw
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    ketone ester

    Participants consume a ketone ester 3x per day for 8 days.

    Dietary Supplement: ketone ester

  • Placebo comparator
    Placebo containing dextrose

    Participants consume a placebo 3x per day for 8 days. The placebo is matched in calories and taste to the ketone ester.

    Dietary Supplement: dextrose (placebo)

Interventions

  • Dietary supplementketone ester

    oral supplement

  • Dietary supplementdextrose (placebo)

    oral supplement calorie and taste matched to ketone supplement

06

What researchers measure

Primary outcomes

  1. Anxiety behavior in Virtual Reality

    Using different scenes in Virtual Reality, parameters of motion behavior such as speed (measured in meters per second) and distance walked (measured in meters) will be assessed using motion tracking technology. These measurements will be combined to generate a composite score of anxiety-related motion behavior.

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  2. Risk propensity on a decision-making task

    The choice (accept/reject) between a risk/gamble or safe option, based on a task paradigm by Liu et al. (2021)

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  3. Competitive confidence in a competition task

    based on a task paradigm by Goette et al., 2015

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  4. Delay Discounting behavior in a computerized task

    based on a task paradigm by Eisenstein et al. 2015

    Time frame: on day 1 of each intervention arm (visit 1 and 3)

  5. Performance in Dual Task

    based on a task paradigm by Szameitat et al., 2002

    Time frame: on day 1 of each intervention arm (visit 1 and 3)

  6. Levels of ketones (ß-Hydroxybutyrate)

    Blood samples

    Time frame: baseline, 15, 30, 60, and 90 minutes post drink-consumption on each of the 4 visits

  7. Insulin

    Blood samples

    Time frame: baseline, 15, 30, 60, and 90 minutes post drink-consumption on each of the 4 visits

  8. Ghrelin

    Blood samples

    Time frame: baseline and + 90 minutes post drink-consumption on each of the 4 visits

  9. Glucose Values

    Continuous Glucose Monitoring through sensors applied to skin

    Time frame: every 15 Minutes from visit 1 to visit 2 and again from visit 3 to visit 4

  10. Blood Glucose

    Blood samples

    Time frame: baseline, 15, 30, 60, and 90 minutes post drink-consumption on each of the 4 visits

  11. Levels of cortisol

    Blood samples

    Time frame: baseline, 15, 30, 60, and 90 minutes post drink-consumption on each of the 4 visits

  12. Electrocardiogram (heart rate)

    Electrophysiological recording

    Time frame: between 30 and 60 minutes post drink-consumption on each of the 4 visits

  13. Electrocardiogram (heart rate variability)

    Electrophysiological recordings

    Time frame: between 30 and 60 minutes post drink-consumption on each of the 4 visits

  14. Electrodermal Activity

    Electrophysiological recordings

    Time frame: between 30 and 60 minutes post drink-consumption on each of the 4 visits

  15. Subjective anxiety levels

    reported by participants on visual analog scale (1-7) during Virtual Reality. 1 being no anxiety to 7 being high anxiety

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  16. Subjective stress levels

    reported by participants on visual analog scale (1-7) during Virtual Reality. 1 being no stress to 7 being high stress

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

Secondary outcomes

  1. Gut microbiome

    Assessed via stool samples after each intervention

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  2. Daily food intake

    Self-reported food intake recorded via FoodApp or handwritten food diary

    Time frame: 5 days of each intervention arm

  3. Trait Anxiety Questionnaire

    Trait version of State-Trait Anxiety Inventory (STAI; Grimm et al. 2009). High scores mean high trait anxiety.

    Time frame: baseline before visit 1

  4. State Anxiety Questionnaire

    State version of State-Trait Anxiety Inventory (STAI; Grimm et al. 2009). High scores mean high state anxiety.

    Time frame: on day 1 and 8 of each intervention arm (visit 1,2,3,4)

  5. Interoception Questionnaire

    Multidimensional Assessment of Interoceptive Awareness (MAIA; Bornemann et al. 2015). High scores mean high interoceptive ability.

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  6. Depression Questionnaire

    Becks Depression Inventar (BDI; Kühner et al. 2007). High scores mean high depression scores

    Time frame: baseline, and on day 8 of each intervention arm (visit 1, 2, and 4)

  7. Mood Questionnaire

    Positive and Negative Affect Schedule (PANAS; Janke et al. 2014). High score on positive scale mean high positive mood and high scores on negative scale mean high negative mood.

    Time frame: on day 1 and 8 of each intervention arm (visit 1,2,3,4)

  8. Inhibition Questionnaire

    Behavioral Inhibition and Activation (BISBAS; Strobel et al. 2001). High scores on inhibition scale mean high inhibition and high scores on activation scale mean high activation.

    Time frame: baseline (visit 1)

  9. Impulsivity Questionnaire

    Barratt Impulsiveness Scale (BIS; Barratt et al. 1965). High scores mean high impulsivity.

    Time frame: baseline (visit 1)

  10. Social Anxiety Questionnaire

    Liebowitz Social Anxiety Scale (Heimberg et al. 1999). High scores mean high scoial anxiety

    Time frame: baseline, and on day 8 of each intervention arm (visit 1, 2, and 4)

  11. Flow Questionnaire

    Flow state scale (FSS; Rheinberg et al. 2002) asked after Dual Task. High scores mean more flow experience during the dual task.

    Time frame: on day 1 of each intervention arm (visit 1 and 3)

  12. Emotional Eating Questionnaire

    Salzburg Emotional Eating Scale (SEES; Meule et al. 2018)

    Time frame: baseline (visit 1)

  13. Stress Eating Questionnaire

    Salzburg Stress Eating Scale (SSES; Meule et al. 2018)

    Time frame: baseline (visit 1)

  14. Dominance Questionnaire

    Social Dominance and Aggressive Dominance Scale (Kalma et al. 1993)

    Time frame: baseline, and on day 8 of each intervention arm (visit 1, 2, and 4)

  15. Autonomy Questionnaire

    Basic Psychological Need Satisfaction and Frustration Scale (BPNSNF; Heissel et al. 2019)

    Time frame: on day 8 of each intervention arm (visit 2 and 4)

  16. Personality Questionnaire

    Big Five Inventory (BFI; John et al. 1991)

    Time frame: baseline (visit 1)

  17. Chronotype Questionnaire

    Morningness-Eveningness Questionnaire (MEQ; Horne \& Östberg, 1976)

    Time frame: baseline (visit 1)

  18. Stress Questionnaire

    Perceived Stress Questionnaire (PSQ; Fliege et al. 2001)

    Time frame: baseline, and on day 8 of each intervention arm (visit 1, 2, and 4)

  19. Subjective anxiety levels

    reported via FoodApp once per day

    Time frame: 5 days of each intervention arm

  20. Subjective stress levels

    reported via FoodApp once per day

    Time frame: 5 days of each intervention arm

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Eisenstein SA, Gredysa DM, Antenor-Dorsey JA, Green L, Arbelaez AM, Koller JM, Black KJ, Perlmutter JS, Moerlein SM, Hershey T. Correction: Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. PLoS One. 2016 Jan 8;11(1):e0147063. doi: 10.1371/journal.pone.0147063. eCollection 2016. No abstract available. PubMed 26744894 ↗
  • Goette L, Bendahan S, Thoresen J, Hollis F, Sandi C. Stress pulls us apart: anxiety leads to differences in competitive confidence under stress. Psychoneuroendocrinology. 2015 Apr;54:115-23. doi: 10.1016/j.psyneuen.2015.01.019. Epub 2015 Feb 19. PubMed 25705012 ↗
  • Liu L, Artigas SO, Ulrich A, Tardu J, Mohr PNC, Wilms B, Koletzko B, Schmid SM, Park SQ. Eating to dare - Nutrition impacts human risky decision and related brain function. Neuroimage. 2021 Jun;233:117951. doi: 10.1016/j.neuroimage.2021.117951. Epub 2021 Mar 12. PubMed 33722669 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Jun 2025, 11 months later.

Of 740 non-industry interventional studies with no phase under Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 11 months is below that.

Counting every sponsor, half of 756 studies reached it within 13 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jul 23, 2024
StartEst.
Jul 18, 2024
Primary completionEst.
Jun 23, 2025
CompletionEst.
Jun 23, 2025
Last update
Jul 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06515717
Lead sponsor
German Institute of Human Nutrition
Responsible party
Prof. Dr. Soyoung Q Park (Prof. Dr., German Institute of Human Nutrition) — Principal investigator
First posted
Jul 23, 2024
Start date
Jul 18, 2024 (estimated)
Primary completion
Jun 23, 2025 (estimated)
Completion
Jun 23, 2025 (estimated)
Last update
Jul 29, 2024

Study contacts

Beatrix Keweloh
Contact
Beatrix.Keweloh@dife.de
+49 33200 882518
Soyoung Q Park, Prof.
Contact
Soyoung.Park@dife.de

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beta-hydroxybutyrate-1,3-butanediol monoester

Start the discussion